ANAB

AnaptysBioB

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-07-20

Current thesis

The bull case is that the completed spin removes structural uncertainty, leaves ANAB with a simpler royalty-management story, and eventually allows investors to value Jemperli and imsidolimab economics plus aggressive capital returns more cleanly once initial post-spin disclosures arrive [#8-K-2026-04-20] [#PR-2026-03-27].

Posture

Constructive

Lead driver

Momentum

What changed

Momentum remains the lead driver in the composite, 7D delta -11.9.

What can break

Any underwhelming capital return execution could weaken the core standalone royalty-equity thesis.

Momentum

Value

Sentiment

Setup hits (3d)

0 · Net Neutral

AI TargetsBase $56.00 · Bull $68.00 · Bear $38.00

Data freshness

Prices

As of 2026-07-20

Fundamentals

As of 2026-07-20 • Vendor: Data Vendor v1

Scores

As of 2026-07-20 • Model: HYBRID_IC_RP

AI Memo

As of 2026-04-21 • Model: RankAlpha Sentiment Codex

Investment thesis

As of 2026-07-20

Supporting evidence

What

Grade B · Constructive

Confidence Medium · Net Neutral

Target $81.50

Why

Momentum83 · Δ7d -11.9

Value41 · Δ7d +0.0

Sentiment51 · Δ7d +8.8

So what

Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.

Lead driver: Momentum · See technicals

Momentum

26% active weight

Current posture

7d trendSoftening

Δ7d

-11.9

Δ21d

-12.2

Value

39% active weight

Current posture

7d trendFlat

Δ7d

+0.0

Δ21d

-0.1

Sentiment

34% active weight

Current posture

7d trendImproving

Δ7d

+8.8

Δ21d

+5.6

Why this grade

Composite grade B. Momentum 82.7 / Value 41.1 / Sentiment 50.9

Fundamentals (TTM)

As of 2026-07-20

Market Cap

$1.49B

Beta

0.36

Shares Out

29.61M

P/E (TTM) · Derived

-109.3

P/S (TTM)

7.06

P/FCF (TTM) · Derived

-423.32

Rev YoY

-8.0%

EPS YoY

+43.6%

Gross Margin

+99.0%

Op Margin

-16.9%

Net Debt

-$21M

Current Ratio

7.58

As of 2026-07-20 • Updated nightlySource: Internal modelMethodology